Vendor profile
VIIVHIV HEALTHCARE, UNIPESSOAL, LDA
PT- Awards
- 16
- Total awarded value
- €19,735,269
- Countries
- countries.PT
- Latest award
- Jul 7, 2026
- Expiring within 12 months
- 0
Award history
| Date | Buyer | Title | Category | Value | Country | Expires | Source |
|---|---|---|---|---|---|---|---|
| 07/07/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | Pharmaceuticals | €1.9M | PT | — | View on TED ↗ |
| 07/07/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | Pharmaceuticals | €373.0K | PT | — | View on TED ↗ |
| 06/30/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | Pharmaceuticals | €232.6K | PT | — | View on TED ↗ |
| 06/30/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | Pharmaceuticals | €166.9K | PT | — | View on TED ↗ |
| 06/30/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR [50 MG CÁP/COMP] | Pharmaceuticals | €434.3K | PT | — | View on TED ↗ |
| 05/12/2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - LAMIVUDINA + DOLUTEGRAVIR [300 MG + 50 MG COMP] | — | €942.7K | PT | — | View on TED ↗ |
| 12/16/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - LAMIVUDINA + DOLUTEGRAVIR [300 MG + 50 MG COMP] | — | €3.7M | PT | — | View on TED ↗ |
| 06/17/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG; CÁP/ COMP] (D564) | — | €759.7K | PT | — | View on TED ↗ |
| 06/17/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG; CÁP/ COMP] (D564) | — | €152.3K | PT | — | View on TED ↗ |
| 04/23/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - DOLUTEGRAVIR [50 MG; CÁP/COMP] (D502) | — | €2.5M | PT | — | View on TED ↗ |
| 04/23/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH (D503) | — | €2.6M | PT | — | View on TED ↗ |
| 04/23/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH (D503) | — | €528.0K | PT | — | View on TED ↗ |
| 04/23/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - DOLUTEGRAVIR [50 MG; CÁP/COMP] (D502) | — | €499.0K | PT | — | View on TED ↗ |
| 04/15/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | €3.8M | PT | — | View on TED ↗ |
| 04/15/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | €400.4K | PT | — | View on TED ↗ |
| 04/15/2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | €765.2K | PT | — | View on TED ↗ |